St. Paul, Minnesota Clinical Trials

A listing of St. Paul, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 406 clinical trials
Savonix Inc-Alzheimer’s Disease Discovery

This study is looking for adults over the age of 22. This is an online cognitive study.Click the link below for more information:https://www.assiststudy.org/

Online studies
Accepts healthy volunteers
Online Study Center
(online study) Contact site
  • 630 views
  • 23 Sep, 2022
  • 1 location
  • Online study
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.

depressive episode
depressive disorder
depressive symptoms
University of Minnesota
 (7.1 away) Contact site
  • 2759 views
  • 17 Sep, 2022
  • +63 other locations
A Phase 4 Study of Nusinersen (BIIB058) Among Patients With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND)

The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received onasemnogene abeparvovec. The secondary objectives of this study are to evaluate the safety and tolerability; and clinical outcomes following treatment with nusinersen in participants …

gene deletion
nusinersen
Children's Specialty Healthcare
 (0.2 away) Contact site
  • 2 views
  • 17 Sep, 2022
  • +18 other locations
A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD Evaluate the distribution of Lp(a) …

Minneapolis Heart Institute Foundation
 (8.0 away) Contact site
  • 0 views
  • 17 Sep, 2022
  • +337 other locations
Gastroschisis Outcomes of Delivery (GOOD) Study

The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a …

Children's MN, Midwest Fetal Care Center
 (8.4 away) Contact site
  • 408 views
  • 16 Sep, 2022
  • +18 other locations
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Novartis Investigative Site
 (7.9 away) Contact site
  • 1 views
  • 14 Sep, 2022
  • +582 other locations
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks …

21-ohd
deficiency
classic congenital adrenal hyperplasia
Neurocrine Clinical Site
 (7.5 away) Contact site
  • 0 views
  • 18 Sep, 2022
  • +36 other locations
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

psoriasis
psoriatic plaque
DMARD
anti-rheumatic drugs
spondylitis
St. Paul Rhuematology, P.A.
 (7.8 away) Contact site
  • 107 views
  • 18 Sep, 2022
  • +97 other locations
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells …

United Hospital
 (1.9 away) Contact site
  • 61 views
  • 19 Sep, 2022
  • +91 other locations
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA)

This is a phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and efficacy of 2 dose regimens of ARGX-117 versus placebo, in participants with MMN previously stabilized with IVIg (intravenous immunoglobulin).

Investigator site 20-US0010126
 (6.3 away) Contact site
  • 0 views
  • 20 Sep, 2022
  • +20 other locations